Through in-house research and partnership programs with pharmaceutical companies and academic groups, we are continuously expanding our extensive portfolio of state-of-the-art biomarkers and antibodies. These qualified antibodies are exclusively available to our partners and collaborators.
Robust and reliable assays for cerebrospinal fluid (CSF) and blood can be developed with these antibodies to detect neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and traumatic brain injury.
Discover our portfolio below. Request a test-sample to verify the unique performance of our materials or let us know how we can help you.
Amyloid-beta is a useful biomarker for the detection of the Alzheimer pathology, even in an early stage. Decreased amyloid-beta 42/40 ratio in CSF and plasma correlates highly with the presence of amyloid plaques in Alzheimer brains.
| ADx101 | Mouse monoclonal antibody against human β Amyloid 1-x | 1 specific |
| ADx102 | Mouse monoclonal antibody against human β Amyloid x-42 | 42 specific |
| ADx103 | Mouse monoclonal antibody against human β Amyloid x-40 | 40 specific |
| ADx401 | Mouse monoclonal antibody against human BACE-1 | |
| ADx402 | Mouse monoclonal antibody against human BACE-1 |
De Kort et al. Ann Neurol. Jun 2023 doi:10.1002/ana.26610
Thijssen et al. Sci Rep. 2021 May 6;11(1):9736.
Janelidze et al, Ann Clin Transl Neurol 2016;3:154.
Total tau and P-tau are good indicators of neuronal damage. P-tau specifically measures damage caused by Alzheimer’s disease. In contrast, total tau is a general marker, which can also be used to determine severe concussion.
| ADx201 | Mouse monoclonal antibody against human total tau | Proline rich domain |
| ADx202 | Mouse monoclonal antibody against human total tau | Proline rich domain |
| ADx204 | Mouse monoclonal antibody against human total tau | N-terminal tau |
| ADx215 | Mouse monoclonal antibody against human total tau | N-terminal tau |
| ADx216 | Mouse monoclonal antibody against human total tau | C-terminal tau |
| ADx217* | Mouse monoclonal antibody against human total tau | N-terminal |
*CSF use only
Rosseels et al, J Biol Chem 2015;290:4059.
Sutphen et al, JAMA Neurol 2015;72:1029.
| ADx252 | Rabbit monoclonal antibody against human P-tau181 | Phosphorylated Threonine 181 specific |
| ADx253 | Mouse monoclonal antibody against human P-tau231 | Phosphorylated Threonine 231 specific |
| ADx254* | Mouse monoclonal antibody (Fab) fragment against human P-tau217 | Phosphorylated Threonine 217 specific |
| RD-085 | Mouse monoclonal antibody against human P-tau217 | Phosphorylated Threonine 217 specific |
*CSF use only
Ashton, Nicholas J. et al. eBioMedicine, Volume 76. 2022 february
De Meyer et al, Ann Clin Transl Neurol. 2022 May
Neurons are interconnected by multiple synapses. In Alzheimer’s disease, synapses show gradual degeneration. Neurogranin and Neuronal Pentraxin 2 (NPTX2) in CSF are good biomarkers for synapse integrity. They will help predict the progression of the disease.
| ADx403 | Mouse monoclonal antibody against human neurogranin | N-terminal |
| ADx451 | Mouse monoclonal antibody against human truncated neurogranin | Specific for C-terminal truncation at P75 |
| ADx409 | Mouse monoclonal antibody against human NPTX-2 | |
| ADx410 | Mouse monoclonal antibody against human NPTX-2 |
Willemse et al, Clin Chem 2018;64:927.
De Vos et al, J Alzheimers Dis 2016;53:1523
The concentration of α-synuclein in CSF is linked to the presence of Lewy bodies in the brain, which are typically found in the brains of Parkinson’s disease patients. Other α-synuclein forms are in development.
| ADx301 | Rabbit monoclonal antibody against human α-synuclein |
Lashuel et al. NPJ Parkinsons Dis. 2022 Oct;8(1):136.
Mollenhauer et al, J Neurochem 2019;149:126.
Schmitz et al, Mol Neurobiol 2019;56:3476.
| ADx206 | Mouse monoclonal antibody against human Nf-L |
| ADx209 | Mouse monoclonal antibody against human Nf-L |
| ADx601 | Rabbit monoclonal antibody against human sTREM-2 |
| ADx602 | Rabbit monoclonal antibody against human sTREM-2 |
ADx markers were developed and commercialized in collaboration with our partners and are adaptable to any technology.
Please get in touch to request more information.
